Manufacturer Notices to Covered Entities

Dr. Reddy's Notice Regarding Fulvestrant NDC Change (PDF - 108 KB)

Organon Notice Regarding Ganirelix NDC Update (PDF - 81 KB)

CooperSurgical Notice regarding NDC change for Paragard (PDF - 76 KB)

Evofem Notice Regarding NDC Change for Solosec (PDF - 216 KB)

GSK Notice Regarding Adjustment to 340B Prices for 4Q22 (PDF - 133 KB)

AbbVie Notice of Price Adjustment Regarding Purchases of Norvir (PDF - 169 KB)

Eli Lilly Notice Regarding Changes to 1Q22 340B Ceiling Prices (PDF - 717 KB)

Xellia Notification of 340B Price Adjustments for Select Products (PDF - 128 KB)

Notice to Covered Entities Regarding TRUQAP NDCs (PDF - 101 KB)

Ascend Laboratories Notice Regarding Offer of 340B Refunds (PDF - 132 KB)

Amgen Notice Regarding Prolia NDCs (PDF - 103 KB)

Amgen Notice of Refunds to 340B Covered Entities 3Q21 – 4Q21 (PDF - 104 KB)

Eli Lilly Notice of Q421 340B Price Changes (PDF - 709 KB)

Amgen Notice Regarding Evenity NDCs (PDF - 36 KB)

Merck Notice Regarding Offer of Refunds to 340B Covered Entities (PDF - 182 KB)

Kedrion Biopharma Inc. Notice Regarding Offer of Refunds (PDF - 133 KB)

GSK Notice Regarding Adjustment to 340B Prices for 3Q22 (PDF - 166 KB)

Mylan Institutional Triamcinolone Acetonide NDC Change Notice (PDF - 93 KB)

SK Life Science Notice Regarding 340B Price Adjustments for Select Products (PDF - 441 KB)

Ingenus NDC discontinuation for Cyclophosphamide and Dr. Reddy's NDC replacement for 340B Replenishment (PDF - 436 KB)

Pfizer Notice of NDC Replacements for 340B Replenishment (PDF - 145 KB)

Apotex Corp. Notice Regarding Refunds to 340B Covered Entities (PDF - 219 KB)

Lilly Notice of Changes to 340B Prices Q2 2021 (PDF - 112 KB)

RedHill Notice Regarding Offer of Refunds to 340B Covered Entities (PDF - 57 KB)

Valinor Notice Regarding Offer of Refunds to 340B Entities (PDF - 463 KB)

Merck Notice to Regarding Offer of 340B Refunds (PDF - 181 KB)

Alnylam Notice Regarding Adjustments to 340B Prices (PDF - 182 KB)

WG CriticalCare Notice to Covered Entities Regarding Refunds (PDF - 114 KB)

Novo Nordisk Notice Regarding Adjustments of 340B Prices on Select Products (PDF - 136 KB)

Cosette Pharmaceuticals Notice to 340B Covered Entities (PDF - 238 KB)

Takeda Notice Regarding Refunds to 340B Covered Entities (PDF - 191 KB)

Novartis Notice of Refunds to 340B Covered Entities (PDF - 345 KB)

Amgen Notice Regarding Refunds to 340B Covered Entities Q1-Q2 2021 (PDF - 135 KB)

J&J Notice Regarding 1Q21 Refunds to Covered Entities (PDF - 174 KB)

Grifols Notice Regarding HyperRHO Replenishment (PDF - 97 KB)

Biocon IG-yfgn Semglee Notice of NDC change (PDF - 86 KB)

Biocon Semglee Vials Notice of NDC change (PDF - 76 KB)

Genentech Notice of Refunds for Perjeta (PDF - 119 KB)

Genentech Notice of Refunds for Klonopin (PDF - 118 KB)

Merck Notice Regarding Refunds to 340B Covered Entities 1Q21 (PDF - 197 KB)

GSK Notice Regarding Adjustment to 340B Prices for 2Q22 (PDF - 124 KB)

Vertex Notice Regarding Adjustment of 340B Prices (PDF - 107 KB)

GSK Notice Regarding Adjustment of 340B Prices for Selected Products (PDF - 138 KB)

Merck Notice Regarding Refunds to 340B Covered Entities (PDF - 170 KB)

Johnson & Johnson Notice Regarding Refunds to 340B Covered Entities (PDF - 171 KB)

Amgen Updated Notice Regarding Availability of Certain Kanjinti NDCs (PDF - 88 KB)

Grifols Notice Regarding Albutein Replenishment (PDF - 104 KB)

Novo Nordisk Notice Regarding 4Q23 340B Price Adjustment for Select Products (PDF - 110 KB)

Novo Nordisk Notice Regarding 340B Price Adjustments for Select Products (PDF - 105 KB)

SpecGx LLC Recalculated 340B ceiling prices for certain products for 3Q20–1Q23 (PDF - 227 KB)

Notice Regarding 340B Price Adjustment for Select Jazz Pharmaceutical Products (PDF - 98 KB)

GSK Notice Regarding Adjustment of 340B Prices for Selected Products 4Q21 (PDF - 138 KB)

Biocon Biologics NDC Change and Replenishment for Insulin Glargine-YFGN (PDF - 79 KB)

Biocon Notice of NDC Change and Replenishment for OGIVRI/FULPHILA (PDF - 226 KB)

Granules Pharmaceuticals Notice of Refunds Q4 2021 to Q2 2023 (PDF - 119 KB)

Noven Recalculated Ceiling Price Notice to Covered Entities (PDF - 176 KB)

Novartis Notice Regarding Locametz and Netspot (PDF - 162 KB)

Eli Lilly Notice Regarding Price Changes (PDF - 113 KB)

Novo Nordisk Notice Regarding Price Adjustments (PDF - 99 KB)

Amgen Notice Regarding Availability of Certain Kanjinti NDCs (PDF - 96 KB)

Novo Nordisk Notice of refunds 1Q-2Q 2023 Ozempic (PDF - 77 KB)

WG Critical Care Notice of Refunds 2Q 2022 (PDF - 537 KB)

Merck Notice of Refunds to Covered Entities 3Q 2020 (PDF - 146 KB)

Johnson & Johnson Notice of Refunds to Covered Entities 3Q2020 (PDF - 156 KB)

Tolmar Notice of Refunds 4Q2017 to 4Q2022 (PDF - 137 KB)

Purdue Notice of 340B Price Changes (PDF - 169 KB)

Meitheal Notice Regarding 340B Refunds (PDF - 195 KB)

GSK Notice of Refunds to Covered Entities Q3 2021 (PDF - 126 KB)

Amgen Notice Regarding Refunds to 340B Covered Entities Q3 2020 – Q4 2020 (PDF - 116 KB)

Vertex Pharma Notice of Refunds to Covered Entities 4Q2022 to Q2 2023 (PDF - 105 KB)

Notice to 340B covered entities regarding ANDEXXA replenishment (PDF - 110 KB)

Amring Refund Notice to 340B Covered Entities (PDF - 162 KB)

VistaPharm Notice Regarding Recalculated 340B Ceiling Prices (PDF - 211 KB)

Eli Lilly and Company Notice of Refunds to Covered Entities 3Q 2020 (PDF - 113 KB)

Novo Nordisk Inc. Notice of Refunds to Covered Entities Q3 2020 (PDF - 110 KB)

Neurocrine Notice Regarding Offer of Refunds to 340B Covered Entities for 3Q2022 – 2Q2023 (PDF - 168 KB)

Amneal Notice Regarding Lioresal Intrathecal Baclofen NDC Change and Replenishment (PDF - 191 KB)

Merck Notice of Refunds to Covered Entities Q2 2020 (PDF - 84 KB)

SK Life Sciences Notice of Refunds to Covered Entities Q3 2021 through Q2 2022 (PDF - 134 KB)

Merck Notice of Refunds to Covered Entities Q1 2020 (PDF - 170 KB)

Amgen Notice of Refunds to Covered Entities Q1-Q2 2020 (PDF - 118 KB)

GSK Notice of Refunds to Covered Entities Q2 2021 (PDF - 126 KB)

Johnson and Johnson Notice Regarding Refunds to  340B Covered Entities (PDF - 122 KB)

Chartwell Rx LLC Notice of Refunds to Covered Entities Q4 2022 (PDF - 112 KB)

Lifestar Pharma Notice of Refunds to Covered Entities Q4 2022 (PDF - 132 KB)

Astellas Notice Regarding Cresemba NDC Change and Replenishment (PDF - 109 KB)

Daiichi Sankyo, Inc Notice to Regarding Refunds for Certain Products (PDF - 111 KB)

Dermavant Sciences Inc. Notice of Refunds to Covered Entities for 2Q 2022 – 1Q 2023 (PDF - 167 KB)

Viatris Notice Regarding NDC Changes (PDF - 91 KB)

Amneal Notice of Refunds to Covered Entities 3Q 2019-3Q 2022 (PDF - 631 KB)

Zydus Pharmaceuticals Notice of Refunds to Covered Entities 1Q 2022-3Q 2022 (PDF - 186 KB)

GSK Notice Regarding Adjustment of 340B Price (PDF - 137 KB)

Astellas Notice Regarding Cresemba NDC Change (PDF - 82 KB)

J&J Notice Regarding Refunds to Covered Entities (PDF - 176 KB)

Alcon Laboratories, Inc. Notice Regarding Refunds to 340B Covered Entities (PDF - 138 KB)

2022

Viatris Notice of Ceiling Price Correction Period (PDF - 305 KB)

Merck Products Notice - Offer of Refunds Multiple quarters 4Q 2019 to 2Q 2022 (PDF - 136 KB)

Novo Nordisk Inc. Notice Regarding Adjustment of 340B Prices for Select Products (PDF - 113 KB)

Lilly Notice of Changes to 340B Prices for 1Q 2022 (PDF - 116 KB)

Astra Zeneca Notice Regarding Calquence Replenishment (PDF - 419 KB)

Purdue Pharma L.P. Notice of Refunds Q1 2020 and Q2 2020 for Select Products (PDF - 160 KB)

GSK Notice of Refunds for 4Q 2020 for Select Products (PDF - 138 KB)

Amgen Notice Regarding Refunds to 340B Covered Entities (PDF - 117 KB)

Merck Products Notice of Refunds Offer Q3 2019 (PDF - 184 KB)

GSK Notice to Covered Entities of Price Adjustment Select Products Q3 2020 (PDF - 158 KB)

Strides Pharma Inc. Notice of Potential 340B Refunds (PDF - 653 KB)

Purdue Pharma LP/Avrio Health LP/Adlon Therapeutics LP Notice of recalculated ceiling prices for Q2 2005-Q2 2021 (PDF - 165 KB)

Eli Lilly Notice of Changes to 2nd Quarter 2019 340B Ceiling Prices (PDF - 115 KB)

Novo Nordisk Inc. Notice Regarding Adjustment of 340B Prices for Select Products (PDF - 103 KB)

e5 Pharma Notice of Offer of Refunds (PDF - 186 KB)

Merck Notice to Offer Refunds (PDF - 149 KB)

BMS Notice regarding 340B Price Adjustments (PDF - 78 KB)

MNK Spec GX Notice of Recalculated 340B Ceiling Prices (PDF - 178 KB)

GSK Notice Regarding Offer of Refunds to 340B Covered Entities (PDF - 133 KB)

Amgen Notice Regarding Refunds to 340B Covered Entities (PDF - 149 KB)

Astellas Notice of Recalculated 340B Ceiling Prices 3Q21-2Q22 (PDF - 130 KB)

BioComp Notice to Covered Entities (PDF - 197 KB)

BMS Refund to 340B Covered Entities (PDF - 72 KB)

Eli Lilly Notice of Changes to 3rd Quarter 2019 340B Ceiling Prices (PDF - 116 KB)

Kala Notice to Refund Covered Entities (PDF - 90 KB)

J&J Notice of Refunds for Q3 and Q4 2019 (PDF - 74 KB)

Akorn Offer of Refund Notice (PDF - 431 KB)

Merck Notice to Offer Refunds (PDF - 184 KB)

Eli Lilly Notice of Changes to Second Quarter 2019 340B Prices (PDF - 136 KB)

GSK Notice Regarding Offer of Refunds to 340B Covered Entities (PDF - 386 KB)

Notice of Adjustment to 340B Price for Vertex Pharmaceuticals' Trikafta® (PDF - 104 KB)

NovoNordisk Notice of Refunds to 340B Covered Entities (PDF - 77 KB)

BMS Notice to Covered Entities of Refunds to 340B Covered Entities (PDF - 145 KB)

Notice of Partial Refund Ipsen's Somatuline® Depot (PDF - 139 KB)

2021

Eli Lilly Notice of Changes to First Quarter 2019 340B Prices (PDF - 139 KB) 

GSK Notice of Refunds to 340B Covered Entities (PDF - 385 KB)

Exelan Notice of Refunds to 340B Covered Entities (PDF - 122 KB)

BioMarin Notice of Refunds to 340B Covered Entities Q4 2020 - Q1 2021 (PDF - 265 KB)

Notification of Supply Allocation: Vidaza (azacitidine) (PDF - 147 KB)

Johnson and Johnson Notice Regarding Refunds to 340B Covered Entities (PDF - 74 KB)

Mytesi Notice of Distribution Network (PDF - 462 KB)

Notification of Global Shortage of Actemra IV (tocilizumab) (PDF - 67 KB)

BioMarin - Notice of Refund to 340B Covered Entities Q1 2019 – Q4 2020 (PDF - 26 KB)

Notice of Limited Distribution for Pegcetacoplan (PDF - 138 KB)

Novartis Notice of 340B Price Adjustment (PDF - 25 KB)

Notice Regarding Adjustment of 340B Prices for Select Products of Novo Nordisk Inc (PDF - 105 KB)

Updated Notice Regarding Limited Distribution Plan for AYVAKIT (avapritinib) (PDF - 519 KB)

Purdue Notification to Covered Entities of Price Recalculations (PDF - 191 KB)

SpecGX LLC (Mallinckrodt) Notice to Covered Entities of Price Recalculations (PDF - 510 KB) 

Verity Notice to Covered Entities of Continuation of Limited Distribution Plan for TRELSTAR (PDF - 139 KB)

Chartwell RX LLC Notice to Covered Entities of Price Recalculations (PDF - 105 KB)

Notice Regarding Adjustment of 340B Prices for Select Products of Xellia Pharmaceuticals (US) LLC (PDF - 126 KB)

Takeda Notification of Updated Limited Distribution Plan for Iclusig (PDF - 159 KB)

Civica Notice to Covered Entities of Price Recalculation (PDF - 121 KB) 

340B Distribution Notice for Nulibry™ (PDF - 145 KB)

Pharmaceutical Associates Inc. Notice to Covered Entities of Price Recalculations (PDF - 157 KB)

Update to 2021 Distribution Plan for Bausch Health Branded Rx NDCs – Renewed Availability through Amerisource Bergen (PDF - 199 KB)

Esperion Notice to Covered Entities of Price Recalculations (PDF - 102 KB)

GSK Notice to Covered Entities of Price Recalculations (PDF - 69 KB)

Notice Regarding Adjustment of 340B Ceiling Prices for Certain Products of Hikma Pharmaceuticals USA, Inc. (PDF - 245 KB)

Beach Products Inc. Labeler 00486 Recalculation K Phos (PDF - 79 KB)

eTon Pharmaceuticals Notice of Limited Distribution Plan for ALKINDI SPRINKLE (PDF - 138 KB)

2020

Notice Regarding Recalculated 340B Covered Entities for Certain Products of Westminster Pharmaceuticals (PDF - 221 KB)

Notice Regarding Adjustment of 340B Prices for Select Products of Kedrion Biopharma Inc. (PDF - 694 KB)

Purdue Notice to Covered Entities of Price Changes for Labeler 59011/67618 (PDF - 511 KB)

Notice Regarding Limited Distribution Plan for Ketorolac Tromethamine Nasal Spray (Sprix® Nasal Spray) (PDF - 420 KB)

UPDATED NOTIFICATION OF SUPPLY ALLOCATION: TICE® BCG BCG LIVE (for intravesical use) (PDF - 135 KB)

REVISED Notice to 340B Covered Entities Regarding BALVERSA® Limited Distribution Plan (PDF - 97 KB)

Notice Regarding Adjustment of 340B Prices for Select Products of Novo Nordisk Inc. (PDF - 115 KB)

Limited Distribution Notice for EVRYSDI (risdiplam) (PDF - 49 KB)

Notice Regarding Recalculated 340B Ceiling Prices for Chiesi USA, Inc. Products Impacted for the Time Period 3Q2016 – 1Q2020 (PDF - 623 KB)

Notice to 340B Covered Entities Regarding Uplizna™ (inebilizumab-cdon) Limited Distribution Network (PDF - 357 KB)

Notice Regarding Recalculated 340B Ceiling Prices for Certain Products of Astellas Pharma US, Inc. (PDF - 127 KB)

Notice Regarding Offer of Refunds to 340B Covered Entities for Purchases of NuvaRing® (PDF - 145 KB)

Notice to 340B Covered Entities: Zestril® Limited Distribution (PDF - 109 KB)

Sunovion Pharmaceuticals, Inc. Limited Distribution Network for KYNMOBI™ (PDF - 76 KB)

Notice to 340B Covered Entities Regarding PALYNZIQ™ (PDF - 62 KB)

Notice on Otezla Replacement NDCs (PDF - 92 KB)

Notice of Price Adjustment to 340B Covered Entities That Purchased L. Perrigo Company Covered Outpatient Drugs Bearing Labeler Code 00113 (PDF - 88 KB) 

Taiho Oncology Inc. Notice of Limited Distribution Network (PDF - 130 KB)

Notice of Price Adjustment to 340B Covered Entities That Purchased ZEVALIN® from Q3 2009 through Q2 2020 (PDF - 91 KB)

Limited Distribution Notice for Opsumit, Tracleer, Uptravi, Veletri, Ventavis, and Zavesca (PDF - 137 KB)

Limited Distribution Plan Notice for Cialis® (tadalafil) Erectile Dysfunction NDCs (PDF - 110 KB)

Notice Regarding Limited Distribution Network for Nourianz (Istradefylline) (PDF - 64 KB)

Alternative Distribution Plan for Certain Bausch Health NDCs and Notice of Covered Entity Refunds (PDF - 126 KB)

Incyte Limited Distribution Network for Pemazyre (PDF - 32 KB)

Incyte Updated Defined Distribution Network for Jakafi (PDF - 40 KB)

Notice Regarding Adjustment of 340B Prices for Select Products of Lupin Pharmaceuticals Inc. (PDF - 519 KB)

Notice of Distribution Model for Qinlock™ (PDF - 364 KB)

UPDATED NOTIFICATION OF SUPPLY ALLOCATION: TICE® BCG BCG LIVE (for intravesical use) (PDF - 181 KB)

Notice of Price Adjustment to PHS Covered Entities (PDF - 33 KB)

Removal of Program Astagraf Limited Distribution Plan (PDF - 229 KB)

Purdue Pharma L.P. and its subsidiaries Aviro Health L.P. and Adlon Therapeutics L.P. Notice of adjusted 340B Prices (PDF - 270 KB)

Bayer Healthcare Limited Distribution Plan for Adempas (PDF - 49 KB)

Limited Distribution Network for DOPTELET® (avatrombopag) Updated 2020 (PDF - 553 KB)

Vertex Pharmaceuticals Inc. Notice of Limited Distribution Plan (PDF - 131 KB)

Notice for Resticted Distribution Network for Sublocade (PDF - 158 KB)

Exelixis Notice of Distribution Model for Cabometyx (PDF - 153 KB)

Notice Regarding Repatha Replacement (PDF - 79 KB)

Updated Notice of Distribution Model for Cometriq (PDF - 131 KB)

Notice of Change in Distribution Model for TYMLOS^® (PDF - 545 KB)

Notice Regarding Recalculated 340B ceiling prices for Apotex Corp (PDF - 43 KB)

Distribution Plan for certain generic products for Bausch Health (PDF - 117 KB)

Limited Distribution Notice for NUPLAZID® (pimavanserin) Tablets and Capsules (PDF - 67 KB)

Notice Regarding Recalculated 340B Ceiling Prices for Certain Products of Astellas Pharma US, Inc. (PDF - 167 KB)

Notice of Change in Distribution Model for Kitabis™ Pak (NDC 24492-850-56) (PDF - 346 KB)

Notice Regarding Adjustment of 340B Prices for Select Products of Purdue Pharma L.P. and Avrio Health L.P. (PDF - 270 KB)

Notice to 340B Covered Entities Regarding Replacement NDCS For Enbrel® (PDF - 95 KB)

2019

Notice to 340B Covered Entities That Purchased Xspire Products (PDF - 134 KB)

340B Limited Distribution Notice for Corlanor® (ivabradine) Oral Solution 5 mg (NDC 55513-0813-28) (PDF - 81 KB)

Notice of Change in Distribution Model for Adrenalin and Vasostrict (PDF - 338 KB)

Notice to 340B Covered Entities Regarding Calcium Acetate (Generic) Capsules (PDF - 86 KB)

Updated 340B Limited Distribution Notice for Xermelo (PDF - 147 KB)

340B Notice Regarding Updated Limited Distribution Plan for Nulojix (belatacept) (PDF - 132 KB)

Daiichi Sankyo Notice to 340B Covered Entities Regarding Turalio™ (PDF - 37 KB)

Notice to 340B Covered Entities Regarding GAMMAKED [Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified] (PDF - 79 KB)

Notice to 340B Covered Entities Related to Axumin™ (NDC # 69932-0001-01) (PDF - 107 KB)

Notice to Covered Entities Regarding Balversa Limited Distribution Plan (PDF - 68 KB)

340B Limited Distribution Notice for OXERVATE (NDC 71981-0020-01) (PDF - 151 KB)

Notice Regarding Recalculated 340B Price for Amphastar Pharmaceuticals, Inc. (PDF - 83 KB)

Notice Regarding Recalculated 340B Ceiling Prices for The Medicines Company Products (PDF - 87 KB)

Notice Regarding Adjustment of 340B Prices for Purdue Pharma L.P. (PDF - 271 KB)

Millennium Pharmaceuticals Notice Regarding Adjustment of 340B Prices for Velcade (PDF - 44 KB)

Vifor Mircera Notice of End of Limited Distribution Plan (PDF - 273 KB)

Catalyst FIRDAPSE® (amifampridine) tablets Notice Regarding Limited Distribution Plan (PDF - 204 KB)

Notice Regarding Adjustment of 340B Prices for Select Products of Kedrion Biopharma, Inc. (PDF - 361 KB)

Notice Regarding Recalculated 340B Prices for Sebela Products (PDF - 105 KB)

Notice Regarding Adjustment of 340B Prices for Select Products of Purdue Pharma L.P. (PDF - 229 KB)

NOTIFICATION OF SUPPLY ALLOCATION: TICE® BCG (BCG LIVE for intravesical use) (PDF - 53 KB)

Array Biopharma Notice of Defined Distribution Network for BRAFTOVl® (encorafenib) and MEKTOVI* (binimetinib) (PDF - 53 KB)

Insmed Limited Distribution Plan for ARIKAYCE (PDF - 51 KB)

2018

Biovertiv Replenishment Notice to Covered Entities for Alprolix and Elocate (PDF - 341 KB)

Akorn Notice to covered entities potential overcharge Methylene Blue 1% 10ml (PDF - 647 KB)

Agios TIBSOVO® Limited Distribution Plan (PDF - 35 KB)

Recalculated 340B Ceiling Prices for Lilly Products (PDF - 71 KB)

Valeant potential overcharge letter labeler 16781 NDC's (PDF - 204 KB)

Notice Regarding Recalculated 340B Ceiling Prices for Genentech Product (PDF - 56 KB)

Shire 340B Ceiling Price Recalculation Notice (PDF - 64 KB)

2017

Almatica Pharma-Tenormin Limited Distribution Plan (PDF - 136 KB)

Johnson and Johnson Healthcare Systems Inc. Notice of 340B Pricing via Cardinal Health Specialty Pharmaceutical Distribution (PDF - 94 KB)

Johnson and Johnson Healthcare Systems Inc. Notice regarding 340B Ceiling Prices for 1Q2017 (PDF - 137 KB)

Notice Regarding Pfizer Defined Oncology Distribution Network (PDF - 68 KB)

2016

Notice Regarding 340B Pricing for Millennium Pharmaceuticals VELCADE (PDF - 40 KB)

Notice Regarding 340B Pricing for BiCNU (PDF - 76 KB)

UPDATE Notice to 340B Covered Entities Regarding Baxalta's VONVENDI (PDF - 129 KB)

340B Notice Regarding Limited Distribution Plan for Imbruvica (ibrutinib) (PDF - 87 KB)

Notice to 340B Covered Entities Regarding 340B Ceiling Prices for Ascend Products (PDF - 113 KB)

Notice to 340B Covered Entities regarding an overcharge that may have occurred for 3 new Valeant NDCs introduced and the issuance of credit (PDF - 74 KB)

Notice Regarding Recalculated 340B Ceiling Prices for Certain Genentech Products impacted for the time period 3Q 2012 through 2Q 2013 (PDF - 124 KB)

Notice to 340B Covered Entities Regarding Recalculated 340B Ceiling Price for Amgen Products and Issuance of Credits (PDF - 47 KB)

2015: Notice Regarding Limited Distribution Network for Reylimid, Pomalyst and Thalomid (PDF - 99 KB)

2014: Bayer Limited Distribution System for Betaseron (PDF - 66 KB)

2013: Bayer Skyla Letter (PDF - 116 KB) 05/31/2013

2009: Limitations on Sales of Venofer® (PDF - 17 KB) 10/29/2009